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Abstract
Secreted reporter molecules offer a means to evaluate biological processes in real time without the need to sacrifice
samples at pre-determined endpoints. Here we have adapted the secreted bioluminescent reporter gene, Metridia
luciferase, for use in a real-time viability assay for mammalian cells. The coding region of the marine copepod gene has been
codon optimized for expression in human cells (hMLuc) and placed under the control of the human b-actin promoter and
enhancer. Metridia luciferase activity of stably transfected cell models corresponded linearly with cell number over a 4-log
dynamic range, detecting as few as 40 cells. When compared to standard endpoint viability assays, which measure the
mitochondrial dehydrogenase reduction of tetrazolium salts, the hMLuc viability assay had a broader linear range of
detection, was applicable to large tissue culture vessels, and allowed the same sample to be repeatedly measured over
several days. Additional studies confirmed that MLuc activity was inhibited by serum, but demonstrated that assay activity
remained linear and was measurable in the serum of mice bearing subcutaneous hMLuc-expressing tumors. In summary,
these comparative studies demonstrate the value of humanized Metridia luciferase as an inexpensive and non-invasive
method for analyzing viable cell number, growth, tumor volume, and therapeutic response in real time.
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Introduction
High throughput cell viability and cytotoxicity assays are a
mainstay for the biologic and therapeutic community. Standard
cell viability assays quantify metabolically active cells through
dehydrogenase activity, which converts tetrazolium salts into
measurable colorimetric products [1,2]. Cell proliferation can also
be quantified by genomic incorporation of radiolabeled Thymi-
dine or 5-bromo-2-deoxyuridine [3]. These standard viability and
cell proliferation assays require cell lysis and therefore a
predetermined and optimized endpoint for each specific condition;
plus additional materials and steps for signal quantification. The
cost of these assays grows with the evaluation of temporal events,
where separate samples and controls are requiredre of these assays
grow with the ps for signal quantificationn of radiolabeled
thymidine ime basis and overcome the need for r for each
measured time point. Cytotoxicity assays can overcome the need
for cell lysis by measuring leaky dehydrogenase activity in the
supernatant, which escapes through the damaged membranes of
dead or dying cells [4,5]. However, the sensitivity of these assays is
generally limited to over 1,000 cells per multiwell plate and the
dynamic range of spectrophotometers. Given the limitations of
these cell viability and cytotoxicity assays, the application of stably
expressed reporters becomes practical for commonly used cell lines
and tumor models [6].
Secreted reporters provide a means to evaluate biologic events
in real time, thus allowing a flexible endpoint and overcoming the
need for multiple replicates of plates in time course studies.
Recently a naturally secreted luciferase was identified and cloned
from the marine copepod Metridia longa [7]. This 23 kilodalton
enzyme, Metridia Luciferase (MLuc), is attractive as a reporter
because it catalyzes a simple bioluminescent reaction which only
requires coelenterazine and oxygen. The product is a blue
bioluminescent signal (lmax=480 nm) which is detected with
high sensitivity over a broad dynamic range in conventional
luminometers [7]. Since this discovery additional secreted
luciferase genes have been cloned, including MpLuc1 and
MpLuc2 from the related Metridia pacifica copepod and Gaussia
luciferase (GLuc) from the Gaussia princeps copepod [8,9]. All of
these secreted proteins have great promise as reporters for high
throughput and non-endpoint monitoring of biologic processes.
Here we have applied codon optimization of the reported MLuc
coding region [7] to generate a humanized version of Metridia
Luciferase, hMLuc. We then created a mammalian cell viability
reporter by placing the hMLuc gene downstream of the
constitutively expressed human b-actin promoter and enhancer,
incorporating the native first intron of the b-actin gene to facilitate
high level expression and efficient processing. The reporter system
was assessed in human and mouse cancer and cell line models.
The results support that the assay is inexpensive, highly sensitive,
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cell culture vessels. In addition, we studied the application of b-
actin driven hMLuc as an ex vivo reporter in tumor bearing mouse
models. The results confirm that serum does inhibit MLuc activity
but, contrary to previous reports [10], we reveal that hMLuc can
be detected as an ex vivo reporter in mouse tumor model systems.
Results
Metridia Luciferase Viability Vector
The human b-actin gene is one of the most highly active genes
in non-muscle mammalian cells and is a standard reference gene
for many biological assays. promoter for b-actin is well charac-
terized and consists of a core promoter and downstream enhancer,
which resides in the first intron [11,12]. strong promoter/
enhancer was applied to generate constitutive expression of the
secreted Metridia longa luciferase reporter. To ensure optimal
expression and translation, the MLuc coding region was human-
ized by codon optimization and engineered with a Kozak
consensus sequence and SV40 polyadenylation signal (Figure 1A).
The humanized coding sequence, hMLuc, has 75.3% sequence
identity with the copepod MLuc. The vector was designed to
produce a spliced transcript, where the b-actin intron 1 and
enhancer are removed, leaving only the coding region of the
bioluminescent reporter.
The resulting reporter vector, pDonor-hb-Actin-hMLuc, was
used to generate stable transfectants in several human (C4-2,
LNCaP, PC-3, HCT-116) and mouse (Tramp-C2) cell lines.
blasticidin selection and clonal isolation, individual clones were
evaluated for MLuc activity in cellular lysates and in the
conditioned media. Figure 1B reveals that the majority of the
MLuc activity was detected in the conditioned media, with little to
no detectible activity in the cell lysate. This demonstrates that the
humanized MLuc is efficiently transcribed, translated, and that
nearly 100% of the reporter is secreted into the media of
transfected mouse and human cell models.
Correlation of reporter activity with cell number
Two cell lines, LNCaP-hMLuc and TC2-hMLuc, were serially
diluted into multiwell tissue culture plates to determine the
correlation of MLuc activity to plated cell number. MLuc activity
was detectable in cell culture media containing as few as 40 cells
and the MLuc activity correlated linearly with cell number to the
highest concentration of cells tested (Figure 2A & B). A correlation
coefficient of 0.991 and 0.983 were obtained over a 4-log range for
LNCaP-hMLuc and TC2-hMLuc, respectively. Further studies
with stable HCT-116-hMLuc colon cancer cells and transiently
transfected HEK293 human embryonic kidney cells support the
sensitivity and linearity of this reporter assay (Figure S1;
Methods S1). This indicates that b-actin-driven hMLuc activity
may be a robust and highly sensitive real time assay for viable cells
number.
hMLuc Viability Assays
To directly compare the hMLuc viability assay to standard
tetrazolium salt based viability assays, LNCaP-hMLuc and TC2-
hMLuc cells were serially diluted over a range of 4-logs and plated
on standard 96-well tissue culture plates. Twenty four hours after
plating, cell viability of the same sample was evaluated by both 5-
(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazoly)-3-(4-sulfophe-
nyl)tetrazolium, inner salt (MTS) reduction, and by hMLuc
Viability Assay. Specifically, a fraction of the conditioned media
was acquired from each plate and quantified for MLuc activity,
while the remaining cells were quantified by MTS assay. Figure 3A
demonstrates that MLuc activity correlated linearly with TC-2-
hMLuc cell number (R
2=0.998) over the full dilution range. The
MTS Assay signal was similarly linear for a portion of the dilution,
but lost linearity at the dilution extremes. When compared to
MLuc, the MTS assay did not show as broad a dynamic range as
the bioluminescent reporter assay. Similarly, in Figure 3B,
LNCaP-hMLuc cell number correlated linearly with MLuc
activity over the full dilution range tested (R
2=0.998), whereas
the linear range of the MTS assay was limited to approximately
5,000 cells. It is important to note that these results do not indicate
that the MTS assay is not functional over a broad range of cell
densities; it merely demonstrates a limitation to the dynamic range
of MTS in a single assay. MTS substrate concentration and
incubation time may be modified for optimum linearity in a lower
or higher cells density samples; however, this will require multiple
plates and optimization at each cell density extreme.
Another limitation of standard viability assays is the format in
which it can be applied. For example, it would be difficult and
expensive to quantify the number of viable cells in a large tissue
culture flask or roller bottle by MTS reduction. Here we assessed
the accuracy of secreted hMLuc to quantify cell number in larger
tissue culture vessels by serially diluting LNCaP-hMLuc cells into
25 cm
2 screw top tissue culture flasks. Media and cells were then
harvested after 24 hours. Viable cell numbers were counted on a
standard hemocytometer by trypan blue exclusion and correlative
hMLuc levels were measured by MLuc assay. The results confirm
a direct linear correlation (R
2=0.998) of MLuc activity with viable
cell number (Figure 3C). Thus, the hMLuc viability assay could be
applied to assess long term cell growth and viability in a variety of
cell vessels.
Real time quantification of cell growth and therapeutic
effect
We next applied the hMLuc viability assay to follow cell growth
and therapeutic effect in an androgen receptor (AR) targeted
therapeutic model. Both LNCaP and TC-2 cell lines are AR
positive and sensitive to androgen deprivation therapy by the
steroidal anti-androgen Bicalutamide.
TC-2-hMLuc and LNCaP-hMLuc cells were grown for several
days in the presence or absence of 10 mM Casodex (Bicalutamide).
Cell viability and therapeutic effect were assessed continuously
over a five day period by measuring aliquots of cellular media for
secreted MLuc activity. The results demonstrate cell growth over
time in both controls; with a significant reduction in growth of the
Bicalutamide treated cells at the last measured time point
(Figure 4). The therapeutic effect was confirmed by MTS assay.
This study reveals the benefits of real time measurements (growth
and therapeutic effect) in a single vessel without the need to first
determine an optimized endpoint.
Secreted MLuc as an ex vivo Reporter Molecule
We completed a pilot study to determine if MLuc activity was
quantifiable ex vivo, in the blood of mice bearing subcutaneous
LNCaP-hMLuc tumors. Blood was collected via tail vein bleed at
the time of tumor measurement and the MLuc activity measured
in the serum over a period of several weeks. The ratio of tumor
volume to MLuc activity per microliter of serum was combined
from several animals and time points to determine their
correlation. Our results indicate that MLuc activity correlated
linearly with measurable tumor volume (Figure 5). These results
were surprising because it had been previously reported that
MLuc activity was undetectable in rat serum and urine [10]. In
that study, Hiramatsu and colleagues identified serum albumin as
a strong inhibitor of MLuc activity. We therefore completed
b-actin hMLuc Viability and Cytotoxicity Assay
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36535Figure 1. Humanized Metridia Luciferase and its cellular partitioning. (A) Sequence Alignment of the codon optimized Metridia Luciferase
(hMLuc) and the Metridia longa Luciferase (MLuc). The engineered Kozak sequence is underlined and the arrow points to the start codons. matches
are indicated by (*) below. Overall similarity of 75.3%. (B) MLuc is secreted from human cells. Various clones of stably expressing hMLuc prostate
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quenched hMLuc activity in a dose dependent manner; nonethe-
less, the signals were above background (Figure 6A). Even at high
serum concentrations, the dynamic range of the assay was retained
and MLuc activity correlated linearly with cell number (Figure 6B).
Therefore we confirm that MLuc activity is sensitive to serum
inhibition, but that it retains sufficient activity to be applicable as
an ex vivo serum reporter in nude mouse tumor models.
Discussion
Bioluminescent reporters provide a method to quantify biologic
processes in real time. From firefly luciferase glowing tumors to
high throughput pharmaceutical screens, the strong signal and
broad dynamic detection range have made bioluminescence
invaluable. Secreted bioluminescent reporters, such as MLuc
and GLuc, provide new means to quantify biological processes
without the need to harvest or lyse cells. Importantly, real time
assessment saves reagents, time, and overcomes the need for a
predetermined endpoint. While bioluminescent activity of non-
secreted reporters can be quantified in intact cells, such as with in
vivo bioluminescent imaging, the reaction is reliant upon efficient
diffusion and retention of the substrate. It is notable that some
bioluminescent substrates, such as firefly luciferin, can be
substrates for multidrug resistant pumps and therefore partitioned
away from the reporter enzyme [13]. In addition, real time
luciferase imaging can be affected by the biodistribution of the
substrate following intravenous or intraperitoneal injection [14].
Therefore, secreted biolouminescent reporters offer a new
mechanism to overcome some of the limitations associated with
cytoplasmic bioluminescent reporters.
While secreted bioluminescent reporters are relatively new, they
have been successfully applied to a variety or studies. MLuc has
been applied to evaluate biological signaling processes in vitro [7],
where GLuc has been used for in vivo imaging [9], ex vivo
quantification of tumor bourdon [15], and cell viability in drug
screens using CMV-promoter driven expression [16]. Here we
provide new evidence that hMLuc, when combined with the b-
actin promoter/enhancer, can efficiently quantify cell viability and
cytotoxicity over a broad dynamic range. Human b-actin is
constitutively expressed at high levels in most cell types and is a
well accepted reference gene or protein in most biologic assays
[17]. However, it is know that b-actin is not a suitable internal
control for every assay [18]; therefore, it may not be applicable to
every mammalian cell type or growth condition. In our studies, b-
actin promoter activity correlated with cell number over a broad
range and proved to be a sensitive reporter for detecting cell
number in vitro in a variety of human and mouse cell lines, different
culture vessels, and experimental conditions.
Currently, there are three commonly applied secreted luciferase
reporters: MLuc, GLuc, and Cypridina Luciferase (CLuc) [19]. The
primary advantage of MLuc, versus GLuc and CLuc, may be in
the efficiency of secretion. In a direct comparison of these three
reporters in HEK293 cells, only 0.86% of hMLuc was retained in
the cells, compared to 2.97% and 7.10% for GLuc and CLuc,
respectively (Figure S2A; Methods S1). Therefore, MLuc may be
more effectively combined with other non-secreted luciferase
enzyme reporters, such as Firefly Luciferase and Renilla Luciferase
(RLuc), in multi-reporter assays. On the other hand, the
advantages of GLuc and CLuc reporters may be in their quantum
yield (Figure S2B). GLuc and CLuc demonstrated 2.6 and 4.7 fold
greater activity, respectively, than MLuc in this study. Other
differences between these three reporters include size (,20 kD for
MLuc and GLuc, versus 61 kD for CLuc) and pH sensitivity. In
addition, modifications of these reporters can dramatically affect
activity. For example, amino truncation of the MLuc enzyme
resulted in greater bioluminescent activity [20].
Recently Hiramatsu and colleagues published a study which
directly compared the activity of MLuc and Secreted alkaline
phosphatase (SEAP) as ex vivo reporters [10]. The study
demonstrated that SEAP was a highly sensitive ex vivo reporter,
whereas MLuc activity was undetectable in the serum or urine of
the applied rat model. Moreover, they revealed the MLuc activity
was significantly inhibited by serum albumin. Here we confirm
that MLuc activity is significantly repressed by serum proteins;
however, we found that MLuc activity was still detectable in high
serum concentrations and that hMLuc activity retained linearity
over the same dynamic range. These results indicate that MLuc is
applicable as an ex vivo reporter; however, its full potential is
cancer cell lines were evaluated for MLuc activity from conditioned medium and cell lysates. The percent value of total MLuc activity per clone is
reported. Error bars represent standard error of the mean from 12 samples. *P,0.05 relative to Media, (t-student test).
doi:10.1371/journal.pone.0036535.g001
Figure 2. Linear quantification of MLuc Activity with cell
number. Serially diluted samples of (A) TC-2-hMLuc and (B) LNCaP-
hMLuc were plated in 96 well plates. Twenty four hours after plating,
100 microliters of conditioned media was taken from each well and
evaluated for MLuc activity. Error bars represent standard error of the
mean from 8 samples. The X-axis represents plated cell number and the
Y-axis represents MLuc Activity (Relative Light Units or RLU) for each
sample. Linear regression analysis indicates an R
2 value of 0.983 for (A)
TC-2-hMLuc cells and 0.991 for (B) LNCaP-hMLuc cells.
doi:10.1371/journal.pone.0036535.g002
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diluted samples of (A) TC-2-hMLuc and (B) LNCaP-hMLuc were plated in
96 well plates. Twenty four hours after plating cell supernatants were
evaluated for MLuc Activity and the remaining cells by MTS viability
assay. The Y-Axis to the left quantifies MLuc activity (RLU) where the Y-
Axis to the right quantifies MTS signal (absorbance of 590 nm light after
four hours of incubation with MTS reagents). The X-axis represents
plated cell number. N=8. Error bars represent standard error of the
mean. Trendlines were fitted for linear regression (MLuc) or Power
curves (MTS) over the given range: (A) TC-2-hMLuc linear regression,
R
2=0.998. (B) LNCaP-hMLuc linear regression R
2=0.998. (C) Serially
diluted LNCaP-hMLuc were plated in 25 cm
2 culture flasks (N=2).
Twenty four hours after plating cell supernatants were evaluated for
MLuc Activity and the remaining cells were counted by trypan blue
exclusions. The Y-axis represents MLuc Activity (RLU) and vertical error
bars represent standard error between samples. The X-axis represents
counted viable cell and horizontal error bars represent standard error
between samples. Linear regression, R
2=0.998.
doi:10.1371/journal.pone.0036535.g003
Figure 4. Evaluation of growth and therapeutic effect by MLuc
Viability Assay. (A) TC2-hMLuc cells and (B) LNCaP-MLuc cells were
treated with a 10 micromolar dose of the anti-androgen Bicalutamide
(Casodex) or vehicle and viable cell numbers over a given time were
evaluated by MTS Assays (N=8). Y-Axis represents fold MLuc activity
relative to time zero. Statistical significance was determine by
student’st-test (*p,0.05). Error bars represent the standard error of
the mean.
doi:10.1371/journal.pone.0036535.g004
Figure 5. Ex vivo quantification of MLuc activity. LNCaP-hMLuc
cells were subcutaneously established in a group of four nude mice.
Once palpable tumors were established, tumor volume was measured
approximately every ten days over several weeks. Blood was
simultaneously drawn at the time of measurement for reference MLuc
activity. The data was grouped into different tumor volume groups. In
all cases, the average serum MLuc activity correlated well with the
average tumor volume (R
2=0.981). Error bars represent standard error
of the mean for each measurement per group.
doi:10.1371/journal.pone.0036535.g005
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detectable as an ex vivo reporter in nude mice bearing subcutaneous
LNCaP-hMLuc tumors. The level of hMLuc activity correlated
with tumor volume in this small study set (Figure 5). Several factors
may have resulted in the greater level of MLuc detection over the
previous study, including the application of different promoters
(CMV versus b-actin promoter/enhancer), animal models (Spra-
gue-Dawley rat versus nude mouse), cellular location (intraperito-
neal versus subcutaneous), codon usage (native versus humanized),
or reporter and cell dose (mesangial cells versus established
tumors).
In summary, these studies validate secreted Metridia Luciferase
as a noninvasive reporter for mammalian cell and tumor models.
Through the use of the b-actin promoter and enhancer, hMLuc
expression was detected with high sensitivity and correlated with
over a broad linear range with viable cell number. This in vitro
viability assay system provides a new mechanism to assess cell
viability and cytotoxicity in real time. Finally these studies reveal
that hMLuc is applicable as an ex vivo reporter, but that detection
can be limited by serum inhibition.
Materials and Methods
Vectors and Cloning
A custom expression vector, pDonor, was generated from
pCMV/Bsd. A Lox71 recombination site was subcloned into
BamHI/HindIII sites using linkers (59-GATCTACCGTTCGTA-
TAGCATACATTATACGAAGTTAT and 39-AGCTA-
TAACTTCGTATAATGTATGCTATACGAACGGTA), fol-
lowed by a second Loxm2/66 site inserted into NheI/Apa sites
using linkers (59- ATAACTTCGTATATGGTTTCTTATAC-
GAACGGTA and CTAGTACCGTTCGTATAAGAAACCA-
TATACGAAGTTATGGCC). These lox site offer a means for
Figure 6. Effect of Serum on MLuc Activity. MLuc conditioned media from TC2-hMLuc was spiked with varying amounts of different serum and
bioluminescence activity was quantified. (A) Various serum used in standard culture medium demonstrated a dose dependent quenching of MLuc
activity. (B) Despite the quenching, the hMLuc viability assay correlated linearly with TC-2-hMLuc cell number over a broad dynamic range in the
presence of ,80% serum. Error bars represent the standard error of the mean. N=8. R
2=0.9894.
doi:10.1371/journal.pone.0036535.g006
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not applied to this project. The Metridia longa luciferase gene was
codon optimized for human expression (referred to herein as
hMLuc) using Vector NTI software (Invitrogen Corporation,
Carlsbad, CA) and custom synthesized, with Kozak sequence and
SV40 polyadenylation signal (Bioclon Inc. San Diego, CA), and
subcloned into the EcoRI/PacI site of pDonor, generating
pDonor-hMLuc. A small fragment of hMLuc was subcloned into
pGL3 using NheI/BsrGI. The human b-actin promoter and
intron-1-enhancer was PCR amplified from genomic DNA
(Primers: R0444: AGACCCAGGCTGTGTAGACCCA and
R0445 CATCATCCATGGTGAGCTGCG) and the resulting
PCR product was subcloned upstream of hMLuc fragments using
NheI/NcoI, generating pGL3-Temp2. The promoter and hMLuc
fragment were then subcloned back into pDonor-hMLuc using
NheI/BsrGI, replacing the CMV promoter, and generating
pDonor-hb-Actin-hMLuc.
Cell Culture
LNCaP, C4–2, and PC-3 human prostate cancer cells and
HEK293 human embryonic kidney cells were obtained from
ATCC. HCT116 colon cancer cells were obtained from Bert
Vogelstein (Johns Hopkins). Tramp-C2 murine prostate cancer
cells were obtained from Norman Greenberg (Baylor College of
Medicine). Stable pDonor- hb-Actin-hMLuc transfectants were
established through Blasticidin selection (Invitrogen Corporation).
Clones were isolated by limited dilution and confirmed by MLuc
assay and genomic PCR. LNCaP-hMLuc, C4-2-hMLuc, and
PC3-hMLuc were grown in RPMI 1640 containing 10% FBS and
5 ug/mL Blasticidin. Tramp-C2-hMLuc (referred to herein as
TC2-hMLuc) was grown in DMEM containing 5% FBS, 5%
NuSerum, 5 ug/mL Blasticidin, 5 mg/mL Insulin, and 0.01 nM
R1881.
Analysis of cellular fractions
1610
6 TC2-hMLuc, LNCaP-hMLuc, C4-2-hMLuc, and PC3-
hMLuc cells in 100 ml of media were plated (minimum of
quadruplets) in 96 well solid white flat bottom polystyrene
microplates (Corning, Cat#3917, Lowell, MA). After 24 hours,
conditioned media was harvested and remaining cells were lysed
with 20 ml passive lysis buffer (Promega, Cat#E194A, Madison,
WI). Media and cell lysate were assayed for MLuc activity using
100 ml of a previously described Renilla buffer [23], consisting of
1.1 M NaCl, 2.2 mM Na2EDTA, 0.22 M KxPO4 (pH 5.1),
0.44 mg/mL BSA, 1.3 mM NaN3, 1.43 mM coelenterazine, with
the final pH=5.0. Assays were read in a Perkin Elmer Micro Beta
luminometer.
Cellular dilution studies
1610
4 TC2-hMLuc and LNCaP-hMLuc cells were serially
diluted 2-fold (10,000–39 cells) and plated in a minimum of
quadruplets in Falcon 96 multiwell plates. After 24 hours 100 mlo f
the conditioned media was transferred to a Corning multiwell
plate and MLuc activity measured as described above. For larger
vessel studies, LNCaP-hMLuc cells were diluted in 25 cm
2 culture
flasks (2.5610
621610
6 cells). After 24 hours 100 ml of the
conditioned media was transferred to a Corning multiwall plate
for MLuc quantification. The remaining cells were harvested by
tryspinization and viable cells counted by trypan blue exclusion.
Correlation coefficients were determined by linear regression
analysis.
MTS and b-actin-hMLuc viability assay comparisons
A 2-fold serial dilution of TC2-hMLuc and LnCaP-hMLuc cells
were plated (minimum of quadruplet) in Falcon 96 well tissue
culture plates (20,000–78 cells). After 24 hours half of the media
(100 ml) was transferred to a Corning multiwell plate for MLuc
Activity assessment. Standard MTS assays (4 hr development)
were performed according to manufacturer9s protocol (Promega
CellTiter96 Non radioactive Cell Proliferation Assay) on the cells
remaining on the plates. Best line fit for MTS assays were obtained
by generating polynomial trendlines while linear regression was
applied for MLuc.
Assay of growth and therapeutic response
500 TC2-hMLuc cells and 1250 LNCaP-hMLuc cells were
plated in two Falcon 96 well tissue culture plates. 24 hrs after
plating samples were quantified by MTS or MLuc (as described
above) to obtain a baseline value. Samples were treated with
vehicle or 10 mM Casodex (Bicalutamide, LKT Laboratories, St
Paul, MN) for the duration of the experiment. Media (50–100 ml)
was collected at 24, 48 & 120 hr intervals for MLuc activity. In
time course assays, cell media was refreshed 24 hours prior to each
time point to establish a fresh background. At 120 hrs a standard
MTS assays was performed.
In Vivo Studies
Studies were performed according to protocols approved by the
Animal Care and Use Committee at Johns Hopkins University.
Subcutaneous tumors were established in male nude mice (nu/nu,
Harlan Laboratories, Inc) with 200 ml of 1:1 matrigel:PBS
containing 1610
6 LnCaP-hMLuc cells. Once measurable, the
tumors and serum MLuc activity were measured weekly. Two
healthy mice were used for background references. In brief, 100 ml
of blood was collected into a serum tube (Sarstedt, Cat#
Microvette 200Z, Newton, NC) via tail vein bleed and tumor
volumes were measured (volume = L x H x W) approximately
every 10 days. 5 ml of serum was diluted into 100 ml of DMEM
media & 100 ml Renilla buffer was added to measure MLuc
activity. The data from four mice were pooled and plotted to
determine the correlation between tumor size and MLuc activity.
Serum Inhibition Assays
MLuc conditioned media was spiked with FBS, cFBS or
NuSerum to a final concentration of 50% or 90%. MLuc Activity
was then measured as described above. To determine assay
linearity, LnCaP-hMLuc cell dilutions were plated on multiwell
plates. The next day 20 ml media from each well was transferred to
a Corning multiwell plate & spiked with 80 ml FBS. 100 ml Renilla
buffer was added to measure the MLuc activity.
Supporting Information
Methods S1 Supplementary Materials and Methods.
(PDF)
Figure S1 Linear quantification of MLuc Activity with
cell number. Serially diluted samples of (A) stable HCT116-
hMLuc and (B) transiently transfected HEK293 cells (pDonor-
hbactin-hMLuc) were plated in 96 well plates (n=5). Twenty four
hours after plating, 100 microliters of conditioned media was taken
from each well and evaluated for MLuc activity. Error bars
represent standard error of the mean. The X-axis represents
plated cell number and the Y-axis represents MLuc Activity
(Relative Light Units or RLU) for each sample. Linear regression
b-actin hMLuc Viability and Cytotoxicity Assay
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2 value of 0.998 for (A) HCT116-hMLuc
cells and 0.987 for (B) HEK293 cells.
(PDF)
Figure S2 Comparison of secreted luciferase con-
structs. HEK293 cells were transiently transfected with RpF-
GFP and pCDNA-3.1-hMLuc, pCDNA-3.1-GLuc, or pCDNA-
3.1-CLuc. Forty eight hours after transfection luciferase activity
was measured from conditioned medium and cell lysates and RLU
activity normalized to GFP expression. the (A) percent activity of
cell fractions as well as the (B) total activity as reported as Relative
Light Units (RLU) are plotted. Error bars represent standard error
of the mean. N=8.
(PDF)
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